ArticleMovement disorders clinical practice2025
Argyrophilic Grain Disease Clinically Presenting as Progressive Supranuclear Palsy with Progressive Gait Freezing.
Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Deciphering Freezing of Gait: What Neuropathology Reveals About an Episodic Phenomenon.The European journal of neuroscience · 2026Review
- Argyrophilic grain disease: epidemiology and association with cognitive decline and parkinsonism.Brain communications · 2025Article
- Dementia with Grains: A Clinical Mimic of Dementia with Lewy Bodies - Case Report.Case reports in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundArgyrophilic grain disease (AGD) is a four-repeat tauopathy characterized by the accumulation of argyrophilic grains. Its primary clinical manifestation is late-onset amnestic dementia. While the extension of argyrophilic grains to the substantia nigra may be related to its potential association with parkinsonism, biochemical analyses are lacking.
objectivesTo elucidate the extent of AGD to the midbrain, including the substantia nigra, using histopathological examination and biochemical analysis in a pathologically proven case of AGD presenting with parkinsonism and cognitive impairment.
methodsWe describe the case of a patient suggestive of progressive supranuclear palsy. Neuropathological and biochemical investigations were performed.
resultsNeurological examination of an 80-year-old man with a 6-year history of gait disturbance revealed parkinsonism, including gait freezing, postural instability, bradykinesia, and cognitive impairment. The patient was diagnosed with progressive supranuclear palsy with progressive gait freezing. Five years later, the patient reported falling backward repeatedly, became wheelchair-bound, and died of pneumonia. Macroscopic observations revealed marked amygdala atrophy. Microscopic findings revealed argyrophilic grains in the limbic system, compatible with Saito stage III, as well as in the substantia nigra and midbrain tegmentum. Western blotting showed an AGD-specific band pattern, and immunoelectron microscopy analyses showed an AGD-specific tau filament of abnormally phosphorylated tau in both the nucleus accumbens and midbrain.
conclusionsThis report further confirmed that AGD presents with parkinsonism, commensurate with AGD pathology and biochemical findings extending to the midbrain. Therefore, AGD should be considered in the differential diagnosis of cases presenting with parkinsonism and cognitive impairment in the older population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.